Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CHFS Nuwellis (CHFS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About Nuwellis Stock (NASDAQ:CHFS) 30 days 90 days 365 days Advanced Chart Get Nuwellis alerts:Sign Up Key Stats Today's Range$1.29▼$1.3750-Day Range$3.53▼$6.0252-Week Range$4.86▼$37.50Volume122,907 shsAverage Volume467,323 shsMarket Capitalization$7.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.Read More… Receive CHFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuwellis and its competitors with MarketBeat's FREE daily newsletter. Email Address CHFS Stock News HeadlinesNuwellis (NASDAQ:NUWE) Stock Quotes, Forecast and News SummaryOctober 2, 2024 | benzinga.comNuwellis, Inc. (NUWE) Interactive Stock Chart - Yahoo FinanceApril 10, 2024 | finance.yahoo.comWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nice stream of income along the way.February 22, 2025 | Behind the Markets (Ad)Why Is Nuwellis (NUWE) Stock Down Today?September 11, 2023 | investorplace.comBetterHelp Online Therapy Review 2023May 4, 2023 | forbes.comBest Prenatal Vitamins Of 2023, According To ExpertsMarch 11, 2023 | forbes.comBest Multivitamins For Kids In 2023, According To ExpertsFebruary 20, 2023 | forbes.comNuwellis Announces Appointment of Chief Financial Officer - GlobeNewswireOctober 19, 2022 | globenewswire.comSee More Headlines CHFS Stock Analysis - Frequently Asked Questions How were Nuwellis' earnings last quarter? Nuwellis, Inc. (NASDAQ:CHFS) issued its quarterly earnings data on Monday, March, 1st. The company reported ($1.57) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.91) by $0.34. The firm earned $2.04 million during the quarter. Nuwellis had a negative net margin of 254.26% and a negative trailing twelve-month return on equity of 173.61%. When did Nuwellis' stock split? Nuwellis shares reverse split before market open on Friday, October 13th 2017. The 1-20 reverse split was announced on Thursday, October 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 12th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Nuwellis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuwellis investors own include Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Biocept (BIOC), VBI Vaccines (VBIV), Immutep (IMMP), NightHawk Biosciences (NHWK) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings3/01/2021Today2/22/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical Equipment Sub-IndustryN/A Current SymbolNASDAQ:CHFS Previous SymbolNASDAQ:SSH CUSIPN/A CIK1506492 Webwww.chf-solutions.com Phone(952) 345-4200FaxN/AEmployees66Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($279.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,110,000.00 Net Margins-254.26% Pretax MarginN/A Return on Equity-173.61% Return on Assets-131.01% Debt Debt-to-Equity RatioN/A Current Ratio6.87 Quick Ratio5.97 Sales & Book Value Annual Sales$5.51 million Price / Sales1.42 Cash FlowN/A Price / Cash FlowN/A Book Value$12.79 per share Price / Book0.10Miscellaneous Outstanding Shares6,037,000Free FloatN/AMarket Cap$7.85 million OptionableNot Optionable Beta1.55 10 Best Stocks to Own in 2025Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:CHFS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuwellis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuwellis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.